T
Thomas F. Eleveld
Researcher at University of Amsterdam
Publications - 9
Citations - 468
Thomas F. Eleveld is an academic researcher from University of Amsterdam. The author has contributed to research in topics: Neuroblastoma & Trametinib. The author has an hindex of 2, co-authored 6 publications receiving 364 citations.
Papers
More filters
Journal ArticleDOI
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
Thomas F. Eleveld,Derek A. Oldridge,Virginie Bernard,Jan Koster,Leo Colmet Daage,Sharon J. Diskin,Linda Schild,Nadia Bessoltane Bentahar,Angela Bellini,Mathieu Chicard,Eve Lapouble,Valérie Combaret,Patricia Legoix-Né,Jean Michon,Trevor J. Pugh,Lori S. Hart,JulieAnn Rader,Edward F. Attiyeh,Jun S. Wei,Shile Zhang,Arlene Naranjo,Julie M. Gastier-Foster,Michael D. Hogarty,Shahab Asgharzadeh,Malcolm A. Smith,Jaime M. Guidry Auvil,Thomas B.K. Watkins,Danny A. Zwijnenburg,Marli E. Ebus,Peter van Sluis,Anne Hakkert,Esther M. van Wezel,C. Ellen van der Schoot,Ellen M. Westerhout,Johannes H. Schulte,Godelieve A.M. Tytgat,M. Emmy M. Dolman,Isabelle Janoueix-Lerosey,Daniela S Gerhard,Huib N. Caron,Olivier Delattre,Javed Khan,Rogier Versteeg,Gudrun Schleiermacher,Jan J. Molenaar,John M. Maris +45 more
TL;DR: It is shown that RAS-MAPK pathway mutations may function as a biomarker for new therapeutic approaches to refractory disease and provide a rationale for genetic characterization of relapse neuroblastomas.
Journal ArticleDOI
RAS-MAPK Pathway-Driven Tumor Progression Is Associated with Loss of CIC and Other Genomic Aberrations in Neuroblastoma.
Thomas F. Eleveld,Linda Schild,Jan Koster,Danny A. Zwijnenburg,Lindy K. Alles,Marli E. Ebus,Richard Volckmann,Godelieve A. Tijtgat,Peter van Sluis,Rogier Versteeg,Jan J. Molenaar +10 more
TL;DR: This work identifies CIC as a powerful tumor suppressor affecting the RAS-MAPK pathway in neuroblastoma and reinforces the importance of mutation-driven activation of this pathway in cancer.
Journal ArticleDOI
Systematic target actionability reviews of preclinical proof-of-concept papers to match targeted drugs to paediatric cancers.
Nil A. Schubert,Caitlin D. Lowery,Guillaume Bergthold,Jan Koster,Thomas F. Eleveld,Ana Rodríguez,David T.W. Jones,Gilles Vassal,Louis Stancato,Stefan M. Pfister,H.N. Caron,Jan J. Molenaar +11 more
TL;DR: The heat map generated from analysis of 161 publications provides a rationale to support drug development in specific paediatric solid and brain tumour types where preclinical data are incomplete or lacking and for which additional preclinical testing is advisable.
Journal ArticleDOI
Chromosome 3p25.3 Gain Is Associated With Cisplatin Resistance and Is an Independent Predictor of Poor Outcome in Male Malignant Germ Cell Tumors
Dennis M Timmerman,Thomas F. Eleveld,Sruthi Sriram,Lambert C. J. Dorssers,Ad J. M. Gillis,Silvia Schmidtova,Katarina Kalavska,Harmen J.G. van de Werken,Christoph Oing,Friedemann Honecker,Michal Mego,Leendert H. J. Looijenga +11 more
TL;DR: Genetic profiling found chromosome 3p25.3 to be strongly associated with cisplatin resistance and poor clinical outcome in male type II GCTs and further characterization of this locus and underlying mechanisms of resistance is warranted to guide development of novel treatment approaches.
Posted ContentDOI
MEK inhibition causes Bim stabilization and sensitivity to Bcl2 family member inhibitors in RAS-MAPK mutated neuroblastoma
Thomas F. Eleveld,Lindy Vernooij,Linda Schild,Bianca Koopmans,Lindy K. Alles,Marli E. Ebus,Peter van Sluis,Huib N. Caron,Jan Koster,Rogier Versteeg,Emmy Dolman,Jan J. Molenaar +11 more
TL;DR: Results show that MEK inhibitors and specific Bcl2 family member inhibitors are a potent combination for RAS-MAPK mutated neuroblastoma tumors.